Asia Pacific Huntington’s Disease Treatment

Asia Pacific Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Drug Type (Approved Drugs (Tetrabenazine and Deutetrabenazine) and Offlabel Drugs), By Distribution Channel, By Age, By Country and Growth Forecast, 2024 - 2031

Report Id: KBV-23452 Publication Date: July-2024 Number of Pages: 123
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Market Report Description

The Asia Pacific Huntington's Disease Treatment Market would witness market growth of 9.7% CAGR during the forecast period (2024-2031).

The China market dominated the Asia Pacific Huntington's Disease Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $55,605.8 Thousands by 2031. The Japan market is registering a CAGR of 9% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 10.4% during (2024 - 2031).

Asia Pacific Huntington's Disease Treatment Market

Information on HD, its signs and symptoms, accessible treatments, and support services gives patients and carers the power to take an active role in their care and make educated decisions. HD can affect swallowing and speech abilities. Nutritional counseling and speech therapy help manage these challenges and maintain overall health.

Emerging neuroprotective strategies aim to preserve neuronal function, protect against neurodegeneration, and potentially delay disease onset or progression. Therapies targeting oxidative stress, mitochondrial function, and other neuroprotective mechanisms aim to enhance neuronal resilience and slow disease progression. Experimental approaches using stem cells to replace damaged neurons and promote neural regeneration are being explored for their potential to restore brain function in HD patients.

As the hospital sector expands in India, there is greater potential for establishing specialized neurology departments and clinics equipped to diagnose and manage complex neurological conditions like Huntington’s disease. The hospital sector in India, which makes up 80% of the country's healthcare business overall, is seeing strong investment demand from domestic and foreign investors, according to the National Investment Promotion and Facilitation Agency of India. The healthcare industry was expected to rise to $132 billion by 2023. In addition, Australia’s high prevalence of HD encourages focused genetic research to understand the disease’s underlying mechanisms and identify potential therapeutic targets. According to the Australian Government, the prevalence rate of Huntington’s disease was estimated at 8.4 per 100,000 people (about 2,160 people). About 830 people diagnosed with Huntington’s disease received a National Disability Insurance Scheme (NDIS) package on 31 December 2019. Hence, the rising hospital sector and the prevalence of HD are driving the market's growth.

Free Valuable Insights: The Global Huntington's Disease Treatment Market is Predict to reach USD 805.1 Million by 2031, at a CAGR of 9.0%

Based on Drug Type, the market is segmented into Approved Drugs (Tetrabenazine and Deutetrabenazine) and Offlabel Drugs. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Store & Retail Pharmacies, and Online Pharmacies. Based on Age, the market is segmented into Below 50 years and Above 50 years. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now

List of Key Companies Profiled

  • Bausch Health Companies, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
  • Hikma Pharmaceuticals PLC
  • Takeda Pharmaceutical Company Limited
  • Sun Pharmaceutical Industries Ltd.
  • Dr.Reddy’s Laboratories Ltd.
  • Neurocrine Biosciences Inc.
  • Pfizer, Inc.
  • F.Hoffmann-La Roche Ltd.

Asia Pacific Huntington’s Disease Treatment Report Segmentation

By Drug Type

  • Approved Drugs
    • Tetrabenazine
    • Deutetrabenazine
  • Offlabel Drugs

By Distribution Channel

  • Hospital Pharmacies
  • Drug Store & Retail Pharmacies
  • Online Pharmacies

By Age

  • Below 50 years
  • Above 50 years

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific


Call: +1(646) 600-5072


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo